NEW HIV TREATMENT: Long lasting injectable approved in Wales
that eligible people living with HIV in England and Wales will soon have routine access to Vocabria (cabotegravir long-acting injection) in combination with Rekambys (rilpivirine long-acting injection).
This comes as the National Institute for Health and Care Excellence (NICE) published positive Final Appraisal Documentation (FAD) – the first time an HIV treatment has ever been appraised and approved by NICE.
This means that eligible people living with HIV in England and Wales will soon be able to receive the complete long-acting injectable regimen once every two months, following an initiation phase (oral lead in and initiation injections), as opposed to regular, daily oral treatment.2
The announcement follows a positive decision from the Scottish Medicines Consortium (SMC) in October 2021, enabling people living with HIV in Scotland to access the long-acting injectable regimen within NHS Scotland.
In a recent survey carried out among people living with HIV, 60% live in fear that their HIV status will be shared without their consent.[iii] More than half (55%) agree that fear of their HIV status being shared unintentionally stops them living their day-to-day life as they would like to, and 56% say they avoid certain social situations as a result.3Sadly, 45% of people with HIV surveyed said they have been forced to share their status because someone spotted the medicine they were taking.3
The combination of cabotegravir and rilpivirine is the first and only once-every-2-month, complete long-acting injectable regimen for virologically suppressed adults living with HIV-1. [iv],[v]
Cabotegravir and rilpivirine are administered as two intramuscular injections in the buttocks, during the same visit at a specialist clinic by a healthcare professional.2 Prior to the initiation of the injections, cabotegravir and rilpivirine oral tablets are taken for approximately one month (at least 28 days) to assess tolerability to the medicines.
According to a recent survey, 85% of people living with the disease agree that having the choice over how often they take their medication would have a positive impact on their life.
Watch the channel on TV